Another study demonstrated that administration of a STAT3-targeting miR-124 in combination with a T cell co-stimulatory aptamer was able to increase CD4+ and CD8+ T cells and decrease macrophage trafficking into the TME in a genetically engineered murine glioma model [156]. The gene discussed is CD8A; the disease is glioma.